Financial Performance Expectations - The company expects a net profit loss between CNY 59,961 million and CNY 86,243 million for the fiscal year 2024, representing a decline of 54.15% to 121.73% compared to the previous year's loss of CNY 38,896 million[3]. - The expected net profit loss after deducting non-recurring gains and losses is projected to be between CNY 57,094 million and CNY 83,377 million, a decrease of 65.75% to 142.05% from last year's loss of CNY 34,446 million[3]. - Total operating revenue is anticipated to be between CNY 161,317 million and CNY 201,317 million, down from CNY 229,929 million in the previous year[3]. Financial Expenses and Impairments - Financial expenses are estimated to be approximately CNY 23,000 million due to significant short-term and long-term borrowings[6]. - Fixed asset depreciation and amortization are expected to impact the company by about CNY 19,000 million[7]. - The company anticipates asset impairment provisions totaling approximately CNY 30,800 million for inventory, construction in progress, fixed assets, and development expenditures[7]. - Other operating expenses related to litigation and overdue interest are projected to be around CNY 8,300 million[8]. - The impact of non-recurring gains and losses on net profit is estimated to be about CNY 2,900 million[9]. Business Outlook - The overall business situation of the company is currently normal, and the impairment amounts are preliminary estimates subject to further evaluation and audit[10]. - The company aims to enhance profitability and achieve sustainable and stable operations moving forward[10].
香雪制药(300147) - 2024 Q4 - 年度业绩预告